Drug intelligence / Profile preview

EMP22

Development stage: Phase 1
Lead developer: Empros Pharma
Modality: Small Molecules
Administration: Oral

Overview

**EMP22** is a modified release formulation of orlistat (120 mg), a gastrointestinal lipase inhibitor designed for weight management. It works by reversibly inhibiting pancreatic and gastric lipases, preventing the hydrolysis of dietary triglycerides into absorbable free fatty acids and monoglycerides, thereby increasing fecal fat excretion and reducing caloric intake from fat. Developed by Empros Pharma, EMP22 is being evaluated in a Phase 1 crossover study (NCT06013163) comparing its pharmacodynamics (fecal fat excretion) to Xenical® (standard orlistat) in healthy volunteers, with TID dosing alongside main meals.[1][3]

Other names: 120 mg modified release orlistat

Targets

LIPF (Gastric lipase)PNLIP (Pancreatic triacylglycerol lipase)

Beyond the preview

Go deeper on EMP22.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on EMP22.

Explore the full profile